PET/CT applications in PET/CT applications in
head and neck cancer head and neck cancer
黃淑華
高雄長庚醫院核子醫學科
高雄長庚紀念醫院正子斷層造影中心
高雄長庚紀念醫院正子斷層造影中心
Positron Emitters Positron Emitters
(Cyclotron) (Cyclotron)
FF--18 (108 min)18 (108 min)
-- FDG (FDG (glycolysisglycolysis/cardiac viability/cerebral /cardiac viability/cerebral metabolism)
metabolism)
CC--11 (20 min)11 (20 min)
-- MethionineMethionine (amino acid metabolism)(amino acid metabolism)
NN--13 (10 min)13 (10 min)
-- Ammonia (myocardial perfusion)Ammonia (myocardial perfusion)
OO--15 (2 min)15 (2 min)
-- water (cerebral perfusion)water (cerebral perfusion)
Oncologic application Oncologic application
Neurologic application Neurologic application
Psychologic Psychologic disorders disorders
Cardiac application Cardiac application
Applications of PET/CT Applications of PET/CT
Lung cancer Lung cancer
Head and neck tumor Head and neck tumor
Colorectal Colorectal
Lymphoma Lymphoma
Melanoma Melanoma
Thyroid cancer Thyroid cancer
Breast cancer Breast cancer
Esophagus Esophagus
Seizure disorder Seizure disorder
Patient preparation Patient preparation
¾¾ No vigorous exercise for one day
No vigorous exercise for one day
¾¾ Fasting> 4 hours except water
Fasting> 4 hours except water
¾¾ Early morning appointment for DM patient
Early morning appointment for DM patient
¾¾ No pregnancy for female patient
No pregnancy for female patient
¾¾ Check Blood sugar < 150 mg
Check Blood sugar < 150 mg
FDG PET in head and neck FDG PET in head and neck
cancer cancer
Staging of head and neck cancer
Staging of head and neck cancer
Primary tumor evaluation by PETPrimary tumor evaluation by PET
Regional nodal staging by PETRegional nodal staging by PET
Distant staging by PETDistant staging by PET
Diagnosis of unknown primary tumor
Diagnosis of unknown primary tumor
Treatment planning
Treatment planning
Therapeutic monitoring
Therapeutic monitoring
Assessment of recurrent head and neck cancer
Assessment of recurrent head and neck cancer
Normal FDG uptake, variants, and pitfalls Normal FDG uptake, variants, and pitfalls
PET/CT in T staging PET/CT in T staging
Sensitive and specific: more than 90% to 95%
Limited in primary tumor extension delineation.
Limited in primary tumor extension delineation.
Dental artifacts on CT or MR images.
Dental artifacts on CT or MR images.
The
The
radiotherpyradiotherpy
planning especially byplanning especially by
delineating the gross tumor volume in intensity
delineating the gross tumor volume in intensity--
modulated
modulated raidation
raidation
therapy (IMRT)therapy (IMRT)
Bone Invasion in Patients with
Oral Cavity Cancer:
Comparison of Conventional CT with PET/CT and SPECT/CT
Radiology 2005
a In the non-attenuation-corrected PET image (filtered back-projection), white spots at the site of non-removable metallicdental artwork are visible.
b An artefact mimicking FDG uptake adjacent to the metallic foreign body is present on the identical slice when using attenuation correction (iterative reconstruction).
c In the co-registered PET/CT image, interpretation of this region is impossible.
a Dental fillings in a non-attenuation-corrected PET image in another patient.
b, c After applying attenuation correction, pseudo-uptake is present adjacent to the metallic dental bridgework. There is a difference between the PETGe68 image (b) and the PETCT scan (c)
• 54-y-old male patient with squamous cell carcinomas of right retromolar area
Standardized uptake value
Tissue activity (uCi/cc)
Administered activity (uCi/g)
SUV =
Mean ROI activity (mCi/ml)
Injected dose (mCi)/body wt(g)
=
Factor affecting SUV
•
Body composition and habitus•
Length of uptake period•
Glucose & insulin level ,renal function•
Partial volume effect•
Recent physical activity•
Inflammation can have elevated SUVPET/CT in N staging PET/CT in N staging
PET has a high positive predictive value, greater than 90% to 95%, and is superior to CT and
MRI with respect to sensitivity and specificity in the detection of nodal disease.
PET is useful in identifying distant metastases and synchronous second malignancies that may not have been detected on routine conventional imaging.
Some series have reported a detection rate of previously unrecognized distant metastases of 27%.
Distant Metastases Staging (M0) and Detection of Synchronous Primary
Tumors
Limitations Limitations
Low grade malignanciesLow grade malignancies
Small lesionSmall lesion
-- Size detectable is a function of reconstructed Size detectable is a function of reconstructed resolution and contrast
resolution and contrast
-- Partial volume effect or respiratory motionPartial volume effect or respiratory motion -- <1mm<1mm
Limited ability to distinguish between residual or recurrent tumor from scar
Inability to biologically characterize disease
Inflammatory diseases
Diagnosis of unknown primary Diagnosis of unknown primary
tumor tumor
There have been conflicting reports with respect to the usefulness of PET in this setting.
In a review of the published series by Rusthoven and colleagues17 the overall ability of PET to detect the occult primary was 25-49%, with a
sensitivity, specificity, and accuracy of 88%, 75%, and 79%, respectively.
INITIAL MANAGEMENT
The ability of PET to alter the TNM staging following conventional imaging, mainly N and M staging
Connell and colleagues found PET/CT altered the TNM staging in 34% of patients, with 10/35 patients up-staged and 2/35 down-staged. In
most cases the alteration was attributable to a change in N staging.
Clinically Node-Negative Neck (N0)
clinical/radiologic N0 is based on perceived risk for less than 15% to 20% occult neck disease
PET: Positive predictive value : 90% ~ 95%;
Negative predictive value : 50% ~ 85%.
Ng and colleagues assessed the usefulness of PET, CT, and MRI in patients who had oral cavity SCC and a
palpably N0 neck
134 patients, 26% were found to have neck metastases
The sensitivity of PET was 51% and this increased after visual correlation with CT/MRI to 57%.
Radiotherapy Planning
PET fusion with RT planning CT scans to assist with definition of tongue base tumor
Post-Radiotherapy Restaging
Assessment of the neck following chemotherapy and RT can be difficult because of residual clinical or
radiologic abnormalities.
Following RT, PET/CT has the ability to distinguish whether there is ongoing metabolic activity within
residual structural abnormalities and has a high negative predictive value, in excess of 95%.
Yao and colleagues assessed the role of PET at a
median of 15 weeks following definitive RT and found the negative predictive value was 100%.
The optimal time for a restaging PET seems to be 12 to 15 weeks following treatment.
THERAPEUTIC MONITORING AND PROGNOSTICATION
PET response following RT seems to have some role in predicting long-term outcome.
Brun and colleagues evaluated the metabolic response (MR) and standardized uptake value (SUV) in 47
patients who had HNSCC
Patients underwent a preatment PET followed by another PET after 1 to 3 weeks of radical RT
Low and high MR FDG PET, with median value as cutoff, was associated with complete response in 96% and 62% (P
=0 .007)
5-year survival, 72% versus 35% (P 5 .0042)
RESTAGING AT RELAPSE AND SURVEILLANCE
In patients treated with HNSCC the 5-year rate of locoregional recurrence, second malignancy, and development of distant metastases are 40%
to 50%, 10% to 30%, and 15% to 20%, respectively.
NOVELTRACERS AND CLINICAL IMPLICATIONS
Hypoxia imaging
Hypoxia has long been recognized as an adverse determinant of RT treatment outcome in head and neck cancer
18F-labelled FMISO PET
fluorine-18 fluoroazomycin arabinoside (FAZA) PET
FDG PET demonstrating uptake at the tongue base and level II node with the FAZA PET demonstrating hypoxia in the node only.
Proliferation Imaging
Increased proliferation is one of the hallmarks of cancer cells.
fluorine-18 fluoro-deoxy-L-thymidine (FLT)
Novel tracers, such as fluorine-18
fluoromisonidazole (FMISO) and fluorine-18
fluoro-deoxy-L-thymidine (FLT), are being evaluated in their ability to biologically
characterize
disease and provide prognostic information